Alvotech Positive Topline Results for Proposed Biosimilar for Simponi

 

• he study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study, which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects, met its primary endpoints.

https://www.globenewswire.com/news-release/2023/11/29/2787524/0/en/Alvotech-Announces-Positive-Top-Line-Results-from-a-Pharmacokinetic-Study-for-AVT05-a-Proposed-Biosimilar-for-Simponi-and-Simponi-Aria.html